Planned MS study will test scans to track worsening
By MS Buddy ·
Summarized from Neuroradiology, Nov 2026 · PubMed · DOI. AI-generated summary. Not medical advice.
127 people with relapsing-remitting MS (flare-ups followed by recovery) and healthy volunteers
Research by Lis van den Boogaard, Jacobus Jansen and 7 colleagues at the Eindhoven University of Technology in the Netherlands.
Can detailed brain scans help predict MS worsening without flare-ups?
Key Takeaway
This planned study will test whether scans of nerve covering can help explain MS worsening without flare-ups or new areas of damage.

What They Found
The abstract describes a study plan, not completed results. Researchers will measure myelin (the protective covering around nerves) using detailed brain scans. They will compare people whose MS worsens with those whose MS does not worsen. Blood tests will look for signs of nerve damage and activity in cells that support nerves. The study aims to find scan signs that predict worsening without flare-ups or new areas of damage.
Who Should Care and Why
The study will include people with relapsing-remitting MS (MS with flare-ups followed by periods of recovery) and healthy volunteers. It focuses on worsening that can happen without flare-ups or new damage visible on standard scans. Researchers will study whether changes in nerve covering help explain this worsening. Healthy volunteers will have a single scan to provide a comparison. Participants with MS can also use a smartphone app to track changes in daily functioning.
Important Considerations
This is a planned study that will follow 97 people with MS over time and scan 30 healthy volunteers. The abstract provides no results showing whether these scans predict worsening. It does not show whether using these scans to guide care improves health.
AI-generated summary — for informational purposes only, not medical advice
Read the original abstract
Published in Neuroradiology by et al.. Reproduced from the PubMed record.
It is increasingly recognized that patients with relapsing-remitting multiple sclerosis (RRMS) may experience disability progression in the absence of clinical relapses and new lesions, a phenomenon known as progression independent of relapse- and magnetic resonance imaging (MRI) activity (PIRMA). The biological basis of this type of progression remains poorly understood. Demyelination is the central pathological hallmark of RRMS. Conventional clinical MRI protocols focus primarily on detecting focal lesions. However, advanced imaging techniques that quantify myelin content can provide additional insights beyond visible lesions, helping to better understand the mechanisms that drive clinical deterioration. Therefore, this study named IMPROving MYelin imaging in patients with relapsing-remitting Multiple Sclerosis (IMPROMYMS study) aims to apply myelin imaging techniques to study clinically defined disease progression in patients with RRMS, by assessing myelin content and comparing it to patients with RRMS without progression of the disease. In total, 97 patients with RRMS will be included and followed for 2.5 years. Participants will undergo MRI scanning at baseline and after 2 years and have regular clinical follow-up visits. Besides conventional MRI, advanced imaging sequences will be scanned, including gradient spin echo (GRASE), multi-echo gradient echo (ME-GRE), diffusion and functional MRI. Additionally, blood samples will be collected longitudinally to assess circulating biomarkers of neuroaxonal damage and astrocytic activation. Participants can also use the smartphone symptom-monitoring app MS Sherpa to enable more frequent monitoring of functional changes in daily life. In addition, 30 healthy controls will be scanned once as a reference group. In this study, we expect to find radiological prognostic markers of an increased risk of developing PIRMA, so that disease management strategies can be altered accordingly.
Categories
Explore more research
Related MS research

11/17/2026
An experimental drug eased nerve-related problems and reduced inflammation in mice with an MS-like d
Read More
11/17/2026
A review explores iron-driven cell death in MS and other diseases involving immune attacks on the bo
Read More
11/16/2026
In mice with damaged nerve coverings, fat-derived stem cells treated with metformin improved repair.
Read More
11/17/2026
Genetic and brain scan data linked inherited brain structure patterns to MS risk. Researchers also f
Read More
11/17/2026
Donated MS brain tissue showed damage in a vision hub. Mouse findings linked local immune cell activ
Read More
11/15/2026
In tissue from mice with an MS-like disease, a lab drug reduced excess chemical release from nerve e
Read MoreNot all studies carry the same weight: sample size, study design and whether results were replicated all matter. The credibility score above reflects the journal, and the original paper is linked under More Details. Read how MS Buddy selects and scores research, and talk to your MS care team before acting on any study.
